Metastatic carcinoma, an aggressive form of skin cancer, presents significant challenges in treatment due to its high mortality rate and limited remedial options. This paper presents a longitudinal multicenter study aiming to estimate the efficacity of CRISPR- Cas9 gene editing for substantiated oncolytic contagion remedy in metastatic carcinoma. The study seeks to assess the safety, feasibility, and remedial eventuality of this innovative approach, which combines the perfection of gene editing with the excrescence- picky nature of oncolytic contagions. the study's design involves retaining cases diagnosed with metastatic carcinoma from multiple centers. Excrescence samples will be attained to identify specific gene mutations associated with the complaint. CRISPR- Cas9 technology will be employed to target and modify these inheritable differences, enhancing the oncolytic contagion's capability to specifically target and destroy cancer cells. The modified contagions will be administered to cases using colorful delivery styles, similar as intratumorally injections or systemic infusions. Throughout the study, clinical and molecular assessments will be performed to cover treatment response and implicit side goods.